Kariva 28 Day Shortage: What Providers and Prescribers Need to Know in 2026

Patients who rely on Kariva 28 Day — a biphasic desogestrel/ethinyl estradiol oral contraceptive — occasionally face difficulty filling their prescriptions due to localized pharmacy stock gaps. While Kariva is not currently listed on the FDA's official drug shortage database, clinicians should understand the supply landscape and be prepared to offer practical guidance to affected patients.

Current Shortage Status (2026)

As of 2026, Kariva 28 Day (desogestrel 0.15 mg / ethinyl estradiol 0.02 mg with 0.01 mg EE phase, manufactured by Teva Pharmaceuticals) is not designated as a drug in shortage by the FDA. National supply is adequate. However, individual pharmacy-level stock gaps occur due to fragmented distribution across multiple branded generics, ordering cycle timing, and regional demand variation.

The original brand Mircette was discontinued. In its place, the market has multiple branded generics: Kariva (Teva), Azurette, Viorele, Pimtrea, Volnea, Bekyree, Kimidess, and Simliya. This fragmentation means any single branded generic may have inconsistent stock at the pharmacy level despite adequate national supply.

Clinical Considerations: AB-Equivalent Substitution

The most clinically straightforward solution for patients unable to fill Kariva is authorization of an FDA AB-equivalent substitution. All of the following contain the same active ingredients at identical doses (0.15 mg desogestrel + 0.02 mg EE for days 1-21, inert days 22-23, 0.01 mg EE days 24-28) and carry an AB therapeutic equivalence rating:

Azurette (28 Day)

Viorele (28 Day)

Pimtrea (28 Day)

Volnea (28 Day)

Bekyree (28 Day)

Simliya (28 Day)

Prescribers can facilitate substitution by writing the prescription as "desogestrel/ethinyl estradiol biphasic (Mircette-type) — substitution permitted" or by adding a note permitting pharmacist substitution. This single intervention can eliminate access barriers for most patients without a clinical visit.

When Substitution Is Not Appropriate

AB-equivalent substitution is generally safe for all patients on Kariva 28 Day, as the pharmacological profile is identical. However, consider the following clinical nuances:

Inactive ingredient allergies: Tablet colors and binders differ between brands. Patients with documented allergies to specific dyes or excipients should have the inactive ingredient list reviewed before substitution.

Patient preference and adherence: Some patients are specifically counseled to remain on the same brand due to prior cycle-related issues. In these cases, continuing to locate the exact product may be preferred over substitution.

Contraindications Relevant to This Drug Class

For patients who cannot continue a combined oral contraceptive (regardless of which branded generic is available), document contraindications and consider alternatives:

Smokers over age 35 (boxed warning — contraindicated in COC use)

History of thromboembolic disorders (DVT, PE, stroke, MI)

Known or suspected breast cancer

Active liver disease or liver tumors

Migraine with aura (increases stroke risk with COC use)

Uncontrolled hypertension

Concurrent HCV combination therapy containing ombitasvir/paritaprevir/ritonavir (contraindicated due to ALT elevation risk)

Key Drug Interactions to Communicate to Patients and Pharmacists

Regardless of which Mircette-equivalent is dispensed, the same drug interaction profile applies:

CYP3A4 inducers (rifampin, carbamazepine, phenytoin, phenobarbital, St. John's Wort): Significantly reduce COC plasma levels, reducing contraceptive efficacy. Recommend backup contraception.

Lamotrigine (Lamictal): COC use significantly decreases lamotrigine plasma concentrations. Seizure management may require lamotrigine dose adjustment when starting or stopping Kariva/equivalent.

HCV direct-acting antivirals: Ombitasvir/paritaprevir/ritonavir combinations are contraindicated. Kariva can be restarted approximately 2 weeks after completion of HCV therapy.

Helping Patients Locate Kariva or Equivalents

Patients who are unable to locate Kariva at their regular pharmacy can be directed to medfinder, a service that calls pharmacies on behalf of patients to find which ones have a specific medication in stock. Results are texted to the patient. This can significantly reduce the burden on patients who may otherwise miss doses while searching for their medication.

Recommend Early Refills and 90-Day Supplies

Prescribers can reduce the frequency of access issues by routinely writing 90-day prescriptions for stable contraceptive patients and documenting early refill authorization. Under the ACA, most private insurance plans must cover FDA-approved contraceptives without cost sharing — confirming this coverage at the point of prescribing can improve patient adherence and reduce prescription gaps.

For a practical step-by-step guide on helping your patients find Kariva in stock, see our provider guide to finding Kariva for patients.